Case of anakinra as a steroid-sparing agent for gout inflammation

University of California, San Francisco, CA, USA.
Arthritis & Rheumatology (Impact Factor: 7.76). 09/2009; 61(9):1268-70. DOI: 10.1002/art.24694
Source: PubMed
5 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Speech recognizers trained in one condition but operating in a different condition degrade in performance. Typical of this situation is when the recognizer is trained under normal conditions but operated in a stressful and noisy environment as in military applications. This paper reports on recognition experiments conducted with a "simulated stress" data base using a baseline algorithm and its modifications. These algorithms perform acceptably well (1 % substitution rate) for a vocabulary of 105 words under normal conditions, but degrade by an order of magnitude under the "stress" conditions. The experiments also show that the speech production variation caused by noise exposure at the ear is far more deleterious than ambient acoustic noise with a noise cancelling microphone.
    Acoustics, Speech, and Signal Processing, IEEE International Conference on ICASSP '86.; 05/1986
  • Source
    Value in Health 05/2007; 10(3). DOI:10.1016/S1098-3015(10)68739-6 · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: NLRP3 inflammasome activation and IL-1beta secretion have recently emerged as a central mechanism in the pathogenesis of disease. Genetically defined syndromes like cryopyrin-associated periodic syndromes (CAPS, cryopyrinopathies) and familial Mediterranean fever (FMF) or diseases associated with NLRP3 activation by danger signals like gout, pseudogout, Alzheimer's disease or type 2 diabetes are included in this group of diseases. The contribution of anakinra, a recombinant, nonglycosylated human IL-1 receptor antagonist, in both the identification and treatment of such syndromes was considerable. Recently, rilonacept, a long-acting IL-1 receptor fusion protein, and canakinumab, a fully humanized anti-IL-1beta monoclonal antibody, have been developed, with the intention to further extent IL-1beta inhibition treatment strategies to a broader spectrum of disorders beyond the characterized autoinflammatory syndromes, offering a more favorable administration profile. On the other hand, the developed caspase-1 inhibitors, even though effective in experimental models, were not proven efficient in the treatment of inflammatory diseases.
    European Journal of Internal Medicine 06/2010; 21(3):157-63. DOI:10.1016/j.ejim.2010.03.005 · 2.89 Impact Factor
Show more